The deal – financial terms of which were not disclosed – will see Quotient’s Co-Formulate work on a number of undisclosed generic products.
Co-Formulate has already developed a paediatric formulation - the chronic drooling treatment Sialanar (glycopyrronium bromide) – for Proveca. The drug was approved by the European Medicines Agency (EMA) last year.
The work on Sialanar was a factor in winning Co-Formulate the new contract according to Proveca director Simon Bryson.
He said “We were very pleased with the outcome of the Sialanar formulation project, and are now delighted to be working with Co-Formulate on a range of further products.”
Bryson told us "We are working on a range of products, both oral liquid and oral solid formulations for children in the cardiovascular and epilepsy therapeutic areas initially."
Quotient acquired fellow Nottingham, UK-based Co-Formulate in December 2015.
At the time, it said the acqusition “reinforces and extends Quotient’s existing pharmaceutical development capabilities across solid, semi-solid and liquid formulations."
This was echoed by Co-Formulate director Huw Jones, who told us "Our approach is based on significant experience within both the Pharma and Healthcare industries in the development of a range of age appropriate paediatric formats and the use of ‘in-house’ taste masking strategies.
"Integration of our development and clinical capabilities enables accelerated clinical validation of any trial formulations."